Login / Signup

Pharmacokinetics under the COVID-19 storm.

Venkatesh Pilla ReddyEman El-KhateebHeeseung JoNatalie GiovinoEmily LythgoeShringi SharmaWeifeng TangMasoud JameiAmin Rastomi-Hodjegan
Published in: British journal of clinical pharmacology (2020)
We demonstrate that systematically collated data on absorption, distribution, metabolism and excretion, human PK parameters, DDIs and organ impairment can be used to verify simulated plasma and lung tissue exposure for drugs repurposed for COVID-19, justifying broader patient recruitment criteria. In addition, the PBPK model developed was used to study the effect of age and ethnicity on the PK of repurposed drugs, and to assess the correlation between lung exposure and relevant potency values from in vitro studies for SARS-CoV-2.
Keyphrases
  • sars cov
  • coronavirus disease
  • respiratory syndrome coronavirus
  • endothelial cells
  • case report
  • big data
  • induced pluripotent stem cells
  • machine learning
  • case control
  • pluripotent stem cells
  • data analysis